19 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28131713	75	Discovery of MK-1832, a Kv1.5 inhibitor with improved selectivity and pharmacokinetics.	Merck Research Laboratories
25987375	20	Discovery of a novel Kv7 channel opener as a treatment for epilepsy.	Pfizer
25087753	240	Prediction of Thorough QT study results using action potential simulations based on ion channel screens.	University of Oxford
25155913	32	Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs) with activity against Pseudomonas aeruginosa.	Astrazeneca
23121096	86	Ion channels as therapeutic targets: a drug discovery perspective.	Pfizer
22793372	66	Discovery of a series of 2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)acetamides as novel molecular switches that modulate modes of K(v)7.2 (KCNQ2) channel pharmacology: identification of (S)-2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)butanamide (ML252) as a potent, brain penetrant K(v)7.2 channel inhibitor.	Vanderbilt University Medical Center
22910039	66	Identification of (R)-N-(4-(4-methoxyphenyl)thiazol-2-yl)-1-tosylpiperidine-2-carboxamide, ML277, as a novel, potent and selective K(v)7.1 (KCNQ1) potassium channel activator.	Vanderbilt University Medical Center
24900334	89	N-Pyridyl and Pyrimidine Benzamides as KCNQ2/Q3 Potassium Channel Openers for the Treatment of Epilepsy.	TBA
11170639	73	Current and novel approaches to the drug treatment of schizophrenia.	Merck Sharp and Dohme Research Laboratories
11356099	20	Recent developments in the biology and medicinal chemistry of potassium channel modulators: update from a decade of progress.	Abbott Laboratories
21296466	20	Design, synthesis and biological activity of pyrazolo[1,5-a]pyrimidin-7(4H)-ones as novel Kv7/KCNQ potassium channel activators.	Hebei Medical University
11689069	18	Synthesis and activity of novel and selective I(Ks)-channel blockers.	Aventis Pharma Deutschland
31566384	134	Development of Chemical Entities Endowed with Potent Fast-Killing Properties against	Glaxosmithkline
30869888	61	Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase Activating Protein (AZD5718) for Treatment of Coronary Artery Disease.	TBA
30538065	48	The discovery and optimization of benzimidazoles as selective Na	Pfizer
28753313	45	Neuroactive Steroids. 2. 3?-Hydroxy-3?-methyl-21-(4-cyano-1H-pyrazol-1'-yl)-19-nor-5?-pregnan-20-one (SAGE-217): A Clinical Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (?-Aminobutyric Acid)	Sage Therapeutics
28626530	71	Discovery of a Series of Indazole TRPA1 Antagonists.	Pfizer